Stocks & Investing
Stocks and Investing
Stocks and Investing 
Thu, July 28, 2011
Wed, July 27, 2011
Market Maker Surveillance Report. NVGN, MSHL, NGSX, CBEH, QCOR, SMNUF, Winning Stocks With Lowest Price Friction For Wednesday
July 27, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3507 companies with "abnormal" market making, 1650 companies with positive Friction Factors and 6163 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN), MARSHALL EDWARDS INC (NASDAQ:MSHL), NEUROGESX INC (NASDAQ:NGSX), CHINA INTEGRATED ENERGY INC (OTC:CBEH), QUESTCOR PHARMACEUTICALS (NASDAQ:QCOR), (OTC:SMNUF). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction
NVGN $0.450 50.56% 1,152,945 51.75% 1,056,437 47.42% 96,508 2,145
MSHL $1.780 152.14% 5,492,177 50.06% 5,312,039 48.42% 180,138 1,012
NGSX $0.400 22.86% 283,228 54.54% 236,094 45.46% 47,134 1,178
CBEH $0.220 25.29% 318,397 44.98% 189,747 26.80% 128,650 5,848
QCOR $6.500 25.00% 3,916,577 49.88% 3,817,646 48.62% 98,931 152
SMNUF $0.254 24.18% 43,000 58.90% 30,000 41.10% 13,000 512
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows NVGN with a dollar gain Wednesday of $0.45000 and a Friction Factor of 2,145 shares. That means that it only took 2,145 more shares of buying than selling to move NVGN higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.
NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN) - Novogen Limited and its subsidiaries engage in the discovery, development, manufacture, export, and marketing of pharmaceuticals and consumer health care products. Its anti-cancer products include Phenoxodiol, a phase III investigational drug for late stage, chemoresistant ovarian cancer and a Phase II clinical trial for prostate and cervical cancers; and Triphendiol, a Phase I completed signal transduction inhibitor for the treatment of cholangiocarcinoma or bile duct cancer, and stage IIB through stage IV malignant melanoma. The companys anti-cancer products also comprise NV-143, a derivative of triphendiol acting as investigational anti-cancer drug; NV-128, a pre-clinical development stage investigational cancer compound using various molecular mechanisms to promote the death of cancer cells; and GLYC-101, a topical gel formulation that stimulates and modulates the natural cascade of wound healing activities in various cell populations. Its consumer health care products consist of various dietary supplement products, such as Promensil and Trinovin that deliver standardized levels of isoflavones, including daidzein, genistein, formononetin, and biochanin. The company distributes its products through direct marketing in Australia, Canada, and the United Kingdom, as well as through third party distribution arrangements internationally. Novogen Limited was founded in 1994 and is headquartered in North Ryde, Australia.
MARSHALL EDWARDS INC (NASDAQ:MSHL) - Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited.
NEUROGESX INC (NASDAQ:NGSX) - NeurogesX, Inc., a biopharmaceutical company, focuses on developing and commercializing novel pain management therapies. The company's lead product includes Qutenza (capsaicin) 8% patch, a non-narcotic analgesic formulated dermal delivery system containing an 8% concentration of synthetic capsaicin. Capsaicin is released from the patch and, with the aid of penetration enhancers, penetrates into the skin during application without significant absorption of capsaicin into the bloodstream. Its Qutenza has been approved by the U.S, Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia; and approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. The company's early stage product pipeline includes NGX-1998, a topical liquid formulation of capsaicin for potential use in neuropathic pain conditions; NGX-1576, NGX-9674, and NGX-5752 prodrugs of acetaminophen for potential use in acute pain, including traumatic pain, post-surgical pain, and fever; and NGX-6052, an opioid prodrug for potential use in chronic pain indications. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is headquartered in San Mateo, California.
CHINA INTEGRATED ENERGY INC (OTC:CBEH) - China Integrated Energy, Inc. operates as an integrated energy company in China. It engages in the wholesale distribution of various finished oil and heavy oil products, including gasoline, diesel, and naphtha to distributors that supply to retail service stations, as well as directly to end users through its retail gas stations. As of March 9, 2010, the company owned and operated 12 retail gas stations in China. It also involves in the production and sale of biodiesel to oil product trading companies, as well as end users comprising gas stations, electric power companies, and shipping companies. The company was formerly known as China Bio Energy Holding Group Co., Ltd. and changed its name to China Integrated Energy, Inc. in September 2009. China Integrated Energy, Inc. was founded in 1999 and is headquartered in Xi'an City, China.
QUESTCOR PHARMACEUTICALS (NASDAQ:QCOR) - Questcor Pharmaceuticals, Inc., a pharmaceutical company, provides prescription drugs for central nervous system and inflammatory disorders. Its primary drug is H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, infantile spasms, opsoclonus myoclonus syndrome, and nephrotic syndrome. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Union City, California.
(OTC:SMNUF) -
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
Contact:
BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net